2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2293

Cardiometabolic Risk and Subclinical Urate Deposits in Patients with Symptomatic Hyperuricemia and Metabolic Syndrome
Abstract Number: 830

Cardiopulmonary Disease Development in Anti-RNA Polymerase III Positive Systemic Sclerosis; Comparative Analyses from an Unselected, Prospective Patient Cohort
Abstract Number: 881

Cardiopulmonary Involvement in Takayasu Arteritis
Abstract Number: 3114

Cardiorespiratory Fitness in Children with Juvenile Idiopathic Arthritis Treated in the Biological Era Is Comparable with Controls- a Cross-Sectional Study
Abstract Number: 1479

Cardiovascular Diseases and Mortality Are Independently Influenced By Carotid Plaque Presence in Rheumatoid Arthritis: The 5-Year Prospective Study
Abstract Number: 423

Cardiovascular Risk and Lipid Screening in Rheumatoid Arthritis Patients in a University Rheumatology Practice: Quality Improvement Project
Abstract Number: 1466

Cardiovascular Risk Assessment in Persons with Rheumatoid Arthritis: A Correlative Study of Non-Invasive Arterial Health Testing with the Inflammatory Burden of Disease
Abstract Number: 1467

Cardiovascular Risk Assessment in Persons with Rheumatoid Arthritis: Non-Invasive Arterial Health Testing to Assess Subclinical Risk of Cardiovascular Disease
Abstract Number: 2170

Cardiovascular Risk in Patients with Psoriasis, Psoriatic and Rheumatoid Arthritis: A Prospective Study Using Secured Anonymised Information Technology Databank in Wales, United Kingdom
Abstract Number: 2611

Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Abstract Number: 3053

Cartilage Loss Primarily Occurs in the Most Affected Tibiofemoral Compartment with No Evidence of a Ceiling Effect Among Advanced-Stage Disease: A Two-Year Longitudinal Study of Data from the Osteoarthritis
Abstract Number: 1311

Causative Pathogens, Antibiotic Susceptibility, and Characteristics of Patients with Bacterial Septic Arthritis over Time
Abstract Number: 1246

Causes and Predictors of Early Readmission in Systemic Lupus Erythematosus
Abstract Number: 2437

Causes of Cesarean Section and Labor Induction in Systemic Lupus Erythematosus and Rheumatoid Arthritis Pregnancies
Abstract Number: 3052

Causes of Death for Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].